AMB304 / Aimed Bio - LARVOL DELTA

AMB304: A next generation ADC with topo I inhibitor, demonstrating robust preclinical efficacy against target overexpression tumors and high tolerability in non-human primate (NHP) (AACR 2025) - "Furthermore, elevated expression of the target is associated with resistance to anti-tumor drugs, such as EGFR TKIs (e.g., Gefitinib) and trastuzumab, via signaling. This study demonstrates that AMB304 is potent ADC with significant anticancer efficacy and an excellent safety profile. Moreover, its superior stability in plasma enhances its potential for clinical treatment. Therefore, AMB304 could be developed as a targeted therapy for advanced solid tumors with high target expression."

Preclinical • Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer